Literature DB >> 16192477

Protective conditioning for acute graft-versus-host disease.

Robert Lowsky1, Tsuyoshi Takahashi, Yin Ping Liu, Sussan Dejbakhsh-Jones, F Carl Grumet, Judith A Shizuru, Ginna G Laport, Keith E Stockerl-Goldstein, Laura J Johnston, Richard T Hoppe, Daniel A Bloch, Karl G Blume, Robert S Negrin, Samuel Strober.   

Abstract

BACKGROUND: Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans.
METHODS: Thirty-seven patients with lymphoid malignant diseases or acute leukemia underwent an experimental conditioning regimen with 10 doses of total lymphoid irradiation (80 cGy each) plus antithymocyte globulin, followed by an infusion of HLA-matched peripheral-blood mononuclear cells from related or unrelated donors who received granulocyte colony-stimulating factor.
RESULTS: Of the 37 transplant recipients, only 2 had acute GVHD after hematopoietic-cell transplantation. Potent antitumor effects in patients with lymphoid malignant diseases were shown by the change from partial to complete remission. In the transplant recipients who underwent conditioning with total lymphoid irradiation and antithymocyte globulin, the fraction of donor CD4+ T cells that produced interleukin-4 after in vitro stimulation increased by a factor of five, and the proliferative response to alloantigens in vitro was reduced, as compared with normal control subjects and control subjects who underwent conditioning with a single dose of total-body irradiation (200 cGy).
CONCLUSIONS: A regimen of total lymphoid irradiation plus antithymocyte globulin decreases the incidence of acute GVHD and allows graft antitumor activity in patients with lymphoid malignant diseases or acute leukemia treated with hematopoietic-cell transplantation. Copyright 2005 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16192477     DOI: 10.1056/NEJMoa050642

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  119 in total

1.  High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.

Authors:  Aaron C Logan; Hong Gao; Chunlin Wang; Bita Sahaf; Carol D Jones; Eleanor L Marshall; Ismael Buño; Randall Armstrong; Andrew Z Fire; Kenneth I Weinberg; Michael Mindrinos; James L Zehnder; Scott D Boyd; Wenzhong Xiao; Ronald W Davis; David B Miklos
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants.

Authors:  J D Scandling; S Busque; S Dejbakhsh-Jones; C Benike; M Sarwal; M T Millan; J A Shizuru; R Lowsky; E G Engleman; S Strober
Journal:  Am J Transplant       Date:  2012-03-08       Impact factor: 8.086

3.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Aristeidis Chaidos; Scott Patterson; Richard Szydlo; Mohammed Suhail Chaudhry; Francesco Dazzi; Edward Kanfer; Donald McDonald; David Marin; Dragana Milojkovic; Jiri Pavlu; John Davis; Amin Rahemtulla; Katy Rezvani; John Goldman; Irene Roberts; Jane Apperley; Anastasios Karadimitris
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

Review 4.  Emerging concepts in haematopoietic cell transplantation.

Authors:  Hao Wei Li; Megan Sykes
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

5.  Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen.

Authors:  Joanna M Schaenman; Sumana Shashidhar; Chanu Rhee; Jonathan Wong; Shelly Navato; Ruby M Wong; Dora Y Ho; Sally Arai; Laura Johnston; Janice M Brown
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-22       Impact factor: 5.742

Review 6.  NKT cells, Treg, and their interactions in bone marrow transplantation.

Authors:  Holbrook E Kohrt; Asha B Pillai; Robert Lowsky; Samuel Strober
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

Review 7.  Prevention of graft-vs.-host disease.

Authors:  Andrew R Rezvani; Rainer F Storb
Journal:  Expert Opin Pharmacother       Date:  2012-07-07       Impact factor: 3.889

Review 8.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

9.  Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.

Authors:  Daniel H Fowler; Miriam E Mossoba; Seth M Steinberg; David C Halverson; David Stroncek; Hahn M Khuu; Frances T Hakim; Luciano Castiello; Marianna Sabatino; Susan F Leitman; Jacopo Mariotti; Juan C Gea-Banacloche; Claude Sportes; Nancy M Hardy; Dennis D Hickstein; Steven Z Pavletic; Scott Rowley; Andre Goy; Michele Donato; Robert Korngold; Andrew Pecora; Bruce L Levine; Carl H June; Ronald E Gress; Michael R Bishop
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

10.  TLI in pediatric patients.

Authors:  A Ocanto; A Escribano; L Glaría; I Rodríguez; C Ferrer; C Huertas; A Pérez; R Morera
Journal:  Clin Transl Oncol       Date:  2019-09-21       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.